Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- Check5 days agoChange DetectedPlain Language Summary section removed from the study page, removing the lay-friendly overview of the trial for general readers. This reduces quick, accessible understanding of the study’s purpose and design for non-experts.SummaryDifference0.0%

- Check12 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor version update to the page's documentation/template.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page's revision metadata was updated from v3.6.3 to v3.6.4, indicating a minor version update to the underlying page.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision: v3.6.3 is now displayed, replacing Revision: v3.6.2. This appears to be an update to the document version without changes to the study content or its features.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page's Revision label changed from v3.6.0 to v3.6.2, signaling a small update to the underlying software/content version.SummaryDifference0.0%

- Check70 days agoChange DetectedThe study page adds new sections for How to Read a Study Record, Common Questions, and How to Join a Study, and updates the Intervention/Treatment labeling; the Revision line updates from v3.5.5 to v3.6.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.